Roughly 25% of breast cancer cases exhibit overexpression of the Human Epidermal Growth Factor Receptor (HER2), a proto-oncogene, that correlates with malignant transformation and notably lower survival rates among breast cancer cases that have undergone lymph node metastasis. Here, ERBB2 is linked to breast cancer.